Study of INCA036978 in Participants With Myeloproliferative Neoplasms (NCT07441694)

🧪 Interventions in This Study

• INCA036978 (DRUG)
• Standard disease-directed therapy (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (54 Sites)

Showing the first 25 of 54 sites.

• University of Alabama At Birmingham — Birmingham, Alabama
• City of Hope-Lennar Foundation Cancer Center — Irvine, California
• Usc Norris Comprehensive Cancer Center — Los Angeles, California
• UCLA Medical Hematology & Oncology — Los Angeles, California
• Yale Cancer Center — New Haven, Connecticut
• University of Miami — Miami, Florida
• Moffitt Cancer Center — Tampa, Florida
• Winship Cancer Institute of Emory University — Atlanta, Georgia
• John Hopkins Hospital — Baltimore, Maryland
• Massachusetts General Hospital — Boston, Massachusetts
• Washington University School of Medicine — St Louis, Missouri
• Memorial Sloan Kettering Cancer Center — New York, New York
• Mount Sinai School of Medicine — New York, New York
• Weill Cornell Medicine — New York, New York
• University of North Carolina At Chapel Hill — Chapel Hill, North Carolina
• Levine Cancer Institute — Charlotte, North Carolina
• Duke University Medical Center, Department of Hematologic Malignancies and Cellular Therapy — Durham, North Carolina
• Cleveland Clinic — Cleveland, Ohio
• Ohio State University — Columbus, Ohio
• Tristar Bmt/Tcto — Nashville, Tennessee
• University of Texas M. D. Anderson Cancer Center — Houston, Texas
• Huntsman Cancer Institute — Salt Lake City, Utah
• Medical College of Wisconsin — Milwaukee, Wisconsin
• Concord General Repatriation Hospital — Concord, New South Wales
• Royal North Shore Hospital — St Leonards, New South Wales

📞 Contact the Study Coordinator

Phone: (855) 463-3463

Email: medinfo@incyte.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Myeloproliferative Neoplasms

• A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms — Birmingham, Alabama
• A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms — Herston, Queensland
• A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms — Duarte, California
• Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation — Chicago, Illinois
• A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms — Phoenix, Arizona

Explore by condition: All Myeloproliferative Neoplasms clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.